InMed Pharmaceuticals (INM) Competitors $2.13 -0.02 (-0.93%) As of 11:28 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock INM vs. LSTA, CLSD, PCSA, TRAW, APLM, SYBX, HOTH, FNCH, EGRX, and LIXTShould you be buying InMed Pharmaceuticals stock or one of its competitors? The main competitors of InMed Pharmaceuticals include Lisata Therapeutics (LSTA), Clearside Biomedical (CLSD), Heatwurx (PCSA), Traws Pharma (TRAW), Apollomics (APLM), Synlogic (SYBX), Hoth Therapeutics (HOTH), Finch Therapeutics Group (FNCH), Eagle Pharmaceuticals (EGRX), and Lixte Biotechnology (LIXT). These companies are all part of the "pharmaceutical products" industry. InMed Pharmaceuticals vs. Its Competitors Lisata Therapeutics Clearside Biomedical Heatwurx Traws Pharma Apollomics Synlogic Hoth Therapeutics Finch Therapeutics Group Eagle Pharmaceuticals Lixte Biotechnology Lisata Therapeutics (NASDAQ:LSTA) and InMed Pharmaceuticals (NASDAQ:INM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability. Does the media favor LSTA or INM? In the previous week, Lisata Therapeutics had 1 more articles in the media than InMed Pharmaceuticals. MarketBeat recorded 2 mentions for Lisata Therapeutics and 1 mentions for InMed Pharmaceuticals. InMed Pharmaceuticals' average media sentiment score of -0.50 beat Lisata Therapeutics' score of -0.77 indicating that InMed Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Lisata Therapeutics Negative InMed Pharmaceuticals Negative Do insiders & institutionals have more ownership in LSTA or INM? 8.9% of Lisata Therapeutics shares are held by institutional investors. Comparatively, 20.1% of InMed Pharmaceuticals shares are held by institutional investors. 9.6% of Lisata Therapeutics shares are held by company insiders. Comparatively, 1.4% of InMed Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has better earnings & valuation, LSTA or INM? InMed Pharmaceuticals has higher revenue and earnings than Lisata Therapeutics. Lisata Therapeutics is trading at a lower price-to-earnings ratio than InMed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLisata Therapeutics$1.07M19.76-$19.99M-$2.23-1.08InMed Pharmaceuticals$4.94M1.03-$8.16M-$12.09-0.18 Which has more volatility and risk, LSTA or INM? Lisata Therapeutics has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, InMed Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500. Is LSTA or INM more profitable? Lisata Therapeutics has a net margin of 0.00% compared to InMed Pharmaceuticals' net margin of -165.12%. Lisata Therapeutics' return on equity of -69.68% beat InMed Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Lisata TherapeuticsN/A -69.68% -59.44% InMed Pharmaceuticals -165.12%-93.19%-74.49% Do analysts prefer LSTA or INM? Lisata Therapeutics currently has a consensus price target of $23.50, suggesting a potential upside of 873.08%. Given Lisata Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Lisata Therapeutics is more favorable than InMed Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lisata Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75InMed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 SummaryLisata Therapeutics beats InMed Pharmaceuticals on 12 of the 17 factors compared between the two stocks. Get InMed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for INM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INM vs. The Competition Export to ExcelMetricInMed PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.07M$2.65B$6.16B$10.63BDividend YieldN/A57.79%5.72%4.85%P/E Ratio-0.1824.0529.4627.34Price / Sales1.03588.41494.53190.41Price / CashN/A27.2425.8230.35Price / Book0.325.4412.476.68Net Income-$8.16M$33.06M$3.32B$276.16M7 Day Performance-3.18%2.54%2.19%0.09%1 Month Performance-6.99%11.77%8.99%3.88%1 Year Performance-63.28%-1.24%64.06%33.52% InMed Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INMInMed Pharmaceuticals0.4763 of 5 stars$2.13-0.9%N/A-55.1%$5.07M$4.94M-0.1810Short Interest ↑LSTALisata Therapeutics2.333 of 5 stars$2.40-1.2%$23.50+879.2%-17.5%$21.02M$1M-1.0830Short Interest ↑CLSDClearside Biomedical1.494 of 5 stars$4.00+0.9%$63.00+1,477.0%-76.3%$20.93M$1.66M-0.7230PCSAHeatwurx2.473 of 5 stars$0.41-8.0%$1.00+146.3%-77.3%$20.59MN/A-0.1820Negative NewsShort Interest ↑Gap DownTRAWTraws Pharma0.7875 of 5 stars$2.86-1.3%N/A-36.9%$20.57M$230K0.0317APLMApollomics0.2502 of 5 stars$18.43+51.3%N/A+135.0%$20.27M$1.49M0.0045Gap UpHigh Trading VolumeSYBXSynlogicN/A$1.73+11.6%N/A+22.7%$20.24M$10K-21.6380HOTHHoth Therapeutics2.6251 of 5 stars$1.53-0.3%$4.50+195.1%+49.7%$20.22MN/A-1.434Positive NewsShort Interest ↓Gap UpFNCHFinch Therapeutics Group1.8182 of 5 stars$12.20flatN/A+2.5%$19.59MN/A-1.38190Short Interest ↓EGRXEagle Pharmaceuticals2.0909 of 5 stars$1.50-6.3%N/A+43.3%$19.48M$257.55M0.00100Gap DownLIXTLixte Biotechnology0.1762 of 5 stars$4.26-1.8%N/A+129.1%$19.18MN/A-3.264Gap Down Related Companies and Tools Related Companies LSTA Alternatives CLSD Alternatives PCSA Alternatives TRAW Alternatives APLM Alternatives SYBX Alternatives HOTH Alternatives FNCH Alternatives EGRX Alternatives LIXT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INM) was last updated on 10/21/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InMed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share InMed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INM Stock Alerts